PMID- 36852694
OWN - NLM
STAT- MEDLINE
DCOM- 20230612
LR  - 20231103
IS  - 2235-0640 (Print)
IS  - 2235-0802 (Electronic)
IS  - 2235-0640 (Linking)
VI  - 12
IP  - 2
DP  - 2023 Apr 1
TI  - Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma.
LID - e230003 [pii]
LID - 10.1530/ETJ-23-0003 [doi]
AB  - BACKGROUND AND OBJECTIVE: Lenvatinib showed promising results in a subgroup of 
      patients with poorly differentiated thyroid carcinoma (PDTC) in the SELECT trial. 
      Our aim was to report the effectiveness and tolerability of lenvatinib in our 
      series of PDTC patients. METHODS: Medical records of eight consecutive patients 
      with PDTC treated with lenvatinib in a single center between January 2019 and 
      October 2022 were retrospectively reviewed. Inclusion criteria were PDTC 
      diagnosis based on Turin criteria and evidence of disease progression in the 
      previous 6 months. RESULTS: Eight PDTC patients received an average dose of 
      lenvatinib of 18.1 mg for a median duration of treatment of 10.3 months. The 
      baseline Eastern Cooperative Oncology Group performance status was >/=2 in 50% of 
      patients. Two patients had unresectable primary tumor. Seven patients showed 
      extrathyroidal disease, particularly mediastinal lymph nodes (85.7%), lung 
      (71.4%), and bone (71.4%). The disease control rate was 100%, with partial 
      response and stable disease in 12.5 and 87.5%, respectively. The median time to 
      best overall response was 3 months, and the median duration of response was 7.5 
      months. Median progression-free survival was 12 months and median overall 
      survival was not reached. At 6, 12, and 18 months, overall survival was 87.5, 
      71.4, and 57.1%, respectively. All patients experienced drug-related adverse 
      effects (AEs). Four (50%) had dose reductions and two (25%) had temporary 
      treatment interruptions. Lenvatinib was stopped in two patients due to grade >/=3 
      AEs. CONCLUSION: Lenvatinib is an effective treatment for real-world PDTC 
      patients. Adequate management of comorbidities and AEs increases treatment 
      tolerability and minimizes dose reductions.
FAU - Roque, Joao
AU  - Roque J
AUID- ORCID: 0000-0002-1191-4997
AD  - Endocrinology, Diabetes and Metabolism Department, Centro Hospitalar 
      Universitario Lisboa Norte, Hospital de Santa Maria, Lisbon, Portugal.
FAU - Nunes Silva, Tiago
AU  - Nunes Silva T
AD  - Endocrinology, Diabetes and Metabolism Department, Instituto Portugues de 
      Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.
AD  - NOVA Medical School | Faculdade de Ciencias Medicas of Universidade NOVA de 
      Lisboa, Lisbon, Portugal.
AD  - Unidade Investigacao Patobiologia Molecular, Instituto Portugues de Oncologia de 
      Lisboa Francisco Gentil, Lisbon, Portugal.
FAU - Regala, Catarina
AU  - Regala C
AD  - Endocrinology, Diabetes and Metabolism Department, Instituto Portugues de 
      Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.
FAU - Rodrigues, Ricardo
AU  - Rodrigues R
AUID- ORCID: 0000-0003-1928-4106
AD  - Unidade Investigacao Patobiologia Molecular, Instituto Portugues de Oncologia de 
      Lisboa Francisco Gentil, Lisbon, Portugal.
FAU - Leite, Valeriano
AU  - Leite V
AD  - Endocrinology, Diabetes and Metabolism Department, Instituto Portugues de 
      Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.
AD  - NOVA Medical School | Faculdade de Ciencias Medicas of Universidade NOVA de 
      Lisboa, Lisbon, Portugal.
AD  - Unidade Investigacao Patobiologia Molecular, Instituto Portugues de Oncologia de 
      Lisboa Francisco Gentil, Lisbon, Portugal.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230328
PL  - England
TA  - Eur Thyroid J
JT  - European thyroid journal
JID - 101604579
RN  - EE083865G2 (lenvatinib)
RN  - 0 (Antineoplastic Agents)
RN  - 135467-92-4 (prolinedithiocarbamate)
MH  - Humans
MH  - *Antineoplastic Agents/adverse effects
MH  - Retrospective Studies
MH  - *Thyroid Neoplasms/drug therapy
MH  - *Adenocarcinoma/chemically induced
PMC - PMC10083649
OTO - NOTNLM
OT  - effectiveness
OT  - lenvatinib
OT  - outcomes
OT  - poorly differentiated thyroid carcinoma
COIS- There is no conflict of interest that could be perceived as prejudicing the 
      impartiality of the research reported.
EDAT- 2023/03/01 06:00
MHDA- 2023/03/01 06:01
PMCR- 2023/03/28
CRDT- 2023/02/28 05:12
PHST- 2023/02/20 00:00 [received]
PHST- 2023/02/27 00:00 [accepted]
PHST- 2023/03/01 06:01 [medline]
PHST- 2023/03/01 06:00 [pubmed]
PHST- 2023/02/28 05:12 [entrez]
PHST- 2023/03/28 00:00 [pmc-release]
AID - e230003 [pii]
AID - ETJ-23-0003 [pii]
AID - 10.1530/ETJ-23-0003 [doi]
PST - epublish
SO  - Eur Thyroid J. 2023 Mar 28;12(2):e230003. doi: 10.1530/ETJ-23-0003. Print 2023 
      Apr 1.